Share page on FacebookShare page on TwitterShare page on LinkedIn
ICON plc
  • Services

    Services

    Our services span the entire lifecycle of product development and commercialisation, and can be adapted to suit small local trials or large global programs.

    Read more
    Services
    Clinical Research ServicesCommercial PositioningConsultingEarly PhaseStrategic SolutionsLaboratoriesLanguage ServicesMedical ImagingReal World IntelligenceSite & Patient Solutions
    Clinical trials during COVID-19.
    COVID-19 clinical operations

    Clinical trials during COVID-19.

    Bringing the clinical trial to the patient with innovation and in-home solutions.
    Decentralised & hybrid clinical solutions

    Bringing the clinical trial to the patient with innovation and in-home solutions.

  • Sectors

    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Sectors
    BiosimilarsBiotechGovernment & Public Health SolutionsMedical DevicePharmaceuticals
    A roadmap to meet 2022 deadlines, while navigating pandemic disruptions.
    The IVDR journey

    A roadmap to meet 2022 deadlines, while navigating pandemic disruptions.

    Developing transformative therapies requires a flexible approach.
    Biotech

    Developing transformative therapies requires a flexible approach.

  • Therapeutics

    Therapeutics

    We have extensive experience in a broad range of therapeutic areas. Managing studies in all major geographies, we have established solid working relationships with the world’s leading investigators.

    Read more
    Therapeutics
    CardiovascularCell and Gene TherapiesCentral Nervous SystemEndocrine & Metabolic DisordersInfectious DiseasesInternal Medicine & ImmunologyMedical DeviceOncologyPaediatricsRare & Orphan DiseasesTransplant ImmunologyWomen's Health
    ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.
    Vaccines

    ICON has lead the development of 18 vaccines resulting in FDA/EMA approvals, including the world’s first approved vaccine for COVID-19.

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Innovation

    Innovation

    We develop integrated technologies to significantly enhance the efficiency and productivity of clients’ drug and device development programs.

    Read more
    Innovation
    FIRECRESTICON Digital PlatformSafety Reporting SolutionOne SearchEvidence PlatformFLEX ADVANTAGEMedical Imaging TechnologyNONMEM ICONIKPDx-POPPubsHubSIMS
    With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.
    FIRECREST

    With travel restrictions due to COVID-19, FIRECREST helps deliver and manage remote training for investigators.

    Harmonising data and services for more integrated decentralised clinical trials.
    ICON Digital Platform

    Harmonising data and services for more integrated decentralised clinical trials.

  • Insights

    Insights

    BioPharma companies and Medical Devices manufacturers face growing operational, regulatory and economic challenges. ICON provides analysis and key insights on these challenges, with practical advice and recommendations.

    Read more
    Insights
    Digital Disruption Patient CentricityRegulatory IntelligenceTherapeutics insightsTransforming TrialsValue Based HealthcareBlogVideosWebinar Channel
    Establishing a platform for improvement
    Diversity and inclusion in clinical trials

    Establishing a platform for improvement

    Patient focused research for better outcomes.
    Decentralised & hybrid clinical trials

    Patient focused research for better outcomes.

  • News & Events

    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    News & Events
    Press releasesIn the NewsMediakitAwardsEventsWebinarsSocial media
    11 - 13 July 2022 - ICON will be exhibiting and speaking at this conference.
    World Orphan Drug Congress US 2022

    11 - 13 July 2022 - ICON will be exhibiting and speaking at this conference.

    27 July 2022 - Register today
    Upcoming Webinar: Evidence synthesis for sparse evidence base, heterogeneous studies, and disconnected networks

    27 July 2022 - Register today

  • About ICON

    About ICON

    Our mission is to help clients accelerate the development of drugs and devices that save lives and improve quality of life.

    Read more
    About ICON
    Company historyICON in Asia PacificICON in Latin AmericaLeadershipQuality
    ICON is committed to making a positive impact on our people, environment and our community.
    Environmental, Social & Governance

    ICON is committed to making a positive impact on our people, environment and our community.

    Partners making a difference.
    ICON and You

    Partners making a difference.

  • Careers
  • Investors
  • Investigators
  • Patients
  • Contact
  • 日本語
  1. Home
  2. News & Events
  3. Press releases

Press releases

  • 22 July 2020

    ICON Reports Second Quarter 2020 Results

    Quarter 2 reported revenue of $620.2 million representing a year on year decrease of 10.8% or 10.3% on a constant currency basis.

  • 27 May 2020

    ICON plc to Present at Jefferies Virtual Healthcare Conference

    Tuesday, June 2, 2020

  • 13 May 2020

    ICON plc to Present at UBS Virtual Global Healthcare Conference

    Wednesday, May 20, 2020

  • 5 May 2020

    ICON appoints new Chief Medical Officer

    ICON announces the appointment of Dr Kristen Buck as the new Chief Medical Officer (CMO).

  • 22 April 2020

    ICON Reports First Quarter 2020 Results

    Reported revenue of $715.1 million representing a 6.0% YoY increase or 6.5% on a constant currency basis. Net business wins of $867 million; a book to bill of 1.21.

  • 9 April 2020

    ICON wins multiple categories in 2020 CRO Leadership Awards third year in a row

    ICON recognised for specialised services offering across product development lifecycle, winning five awards overall.

  • 3 April 2020

    ICON signs new Service Agreement with Pfizer

    Agreement builds on the companies' existing relationship, under which ICON provides global expertise in the planning, execution, management and conduct of clinical trials.

  • 23 March 2020

    ICON launches the Coronavirus Observatory

    The Coronavirus Observatory applies powerful AI analysis and data visualisation to COVID-19 news and social media, providing updates on the latest vaccine trials.

  • 3 March 2020

    ICON plc to Present at Barclays Global Healthcare Conference 2020

    The presentation will be webcast live from 10.15am EDT, Tuesday, March 10, 2020.

  • 19 February 2020

    ICON Acquires MedPass International

    Acquisition expands ICON’s global Medical Device and Diagnostic Research Services

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • ...
  • 14
In this section
In this section
  • Press releases
  • In the News
  • Mediakit
    • Facts and figures
    • ICON Spokespeople
  • Awards
  • Events
    • Industry events
    • Webinars
    • Workshops
    • Financial Times Global Pharmaceutical and Biotechnology Conference
  • Webinars
  • Social media

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media

What’s happening in ICON

ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Services
  • Insights
  • Innovation
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Social media dashboard
  • LinkedIn
  • Twitter
  • Facebook
  • Youtube
  • © 2022 ICON plc
  • Disclaimer
  • Privacy
  • Site Cookies

Connect with us

Contact usSubmit proposal requestUpdate Email PreferencesGlobal office locatorICON on social media